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Abstract
Background: Specific phobia (SP) is a relatively common disorder associated with high levels of psychiatric
comorbidity. Because of its early onset, SP may be a useful early marker of internalizing psychopathology, especially
if generalized to multiple situations. This study aimed to evaluate the association of childhood generalized SP with
comorbid internalizing disorders.
Methods: We conducted retrospective analyses of the cross-sectional population-based World Mental Health
Surveys using the Composite International Diagnostic Interview. Outcomes were lifetime prevalence, age of onset,
and persistence of internalizing disorders; past-month disability; lifetime suicidality; and 12-month serious mental
illness. Logistic and linear regressions were used to assess the association of these outcomes with the number of
subtypes of childhood-onset (< 13 years) SP.
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Results: Among 123,628 respondents from 25 countries, retrospectively reported prevalence of childhood SP was
5.9%, 56% of whom reported one, 25% two, 10% three, and 8% four or more subtypes. Lifetime prevalence of
internalizing disorders increased from 18.2% among those without childhood SP to 46.3% among those with one
and 75.6% those with 4+ subtypes (OR = 2.4, 95% CI 2.3–2.5, p < 0.001). Twelve-month persistence of lifetime
internalizing comorbidity at interview increased from 47.9% among those without childhood SP to 59.0% and
79.1% among those with 1 and 4+ subtypes (OR = 1.4, 95% CI 1.4–1.5, p < 0.001). Respondents with 4+ subtypes
also reported significantly more disability (3.5 days out of role in the past month) than those without childhood
SP (1.1 days) or with only 1 subtype (1.8 days) (B = 0.56, SE 0.06, p < 0.001) and a much higher rate of lifetime
suicide attempts (16.8%) than those without childhood SP (2.0%) or with only 1 subtype (6.5%) (OR = 1.7, 95% CI
1.7–1.8, p < 0.001).
Conclusions: This large international study shows that childhood-onset generalized SP is related to adverse
outcomes in the internalizing domain throughout the life course. Comorbidity, persistence, and severity of
internalizing disorders all increased with the number of childhood SP subtypes. Although our study cannot
establish whether SP is causally associated with these poor outcomes or whether other factors, such as a shared
underlying vulnerability, explain the association, our findings clearly show that childhood generalized SP
identifies an important target group for early intervention.
Keywords: Specific phobia, Internalizing disorders, Early markers, Comorbidity, Suicidality,
Introduction
Anxiety and mood disorders are major contributors to
the global disease burden [1] due partly to their high
prevalence [2], early onset [3], and chronic or recurrent
course [4–6]. Although much effort has been devoted to
improving the course of these disorders, treatment is
still insufficient to avert most of the burden [7–11].
Consequently, prevention may be a necessary alternative
strategy.
Comorbidity between mental disorders is common
[12, 13], which has led theorists to posit a latent struc-
ture of psychopathology, reducing a variety of disorders
to a limited set of domains [14]. These domains, of
which the internalizing and externalizing have been con-
firmed most frequently [15–20], are thought to represent
core psychopathological processes underlying the varied
clinical manifestations of disorders. If so, targeting these
underlying processes might offer new opportunities for
prevention. Internalizing disorders, for example, develop
at very different ages: specific phobia (SP) has a median
age of onset at 8 years old [21], whereas major depres-
sive disorder (MDD) and generalized anxiety disorder
(GAD) have median onset at 30–40 years old [3, 22]. If
interventions could successfully treat the earlier disor-
ders in this domain, this might lead to reductions in the
subsequent onset, persistence, or severity of other disor-
ders in the same domain.
Although SP is often considered a relatively mild dis-
order [23, 24], the structure of psychopathology model
suggests that it might identify persons with a vulnerabil-
ity for more serious later disorders in the same domain.
In support of this possibility, SP has been associated
with increased risk of later-onset disorders in the
internalizing domain [21, 25–34]. Importantly, persons
with SP may have only a single fear, or they may have
many (e.g., of spiders, storms, blood, and heights). Some
evidence suggests that persons with multiple fears have
a greater risk of comorbidity and impairment [21, 29, 33,
35, 36], suggesting that generalized SP may be a marker
of particularly high internalizing vulnerability.
With an eye toward early intervention, SP with an on-
set in childhood is of greatest interest, but to date, no
study has examined internalizing comorbidity in this
group of people. Furthermore, information about other
important aspects of comorbidity, such as age of onset,
persistence, and severity, and other outcomes, such as
suicidality, is largely lacking. In this paper, we therefore
examine these outcomes. We focus on the number of
phobia subtypes as a marker of generalization of the
underlying psychopathological process, expecting worse
outcomes among persons reporting more fears.
Methods
Survey samples
Data came from the World Mental Health Surveys
(WMHS), which include cross-sectional surveys adminis-
tered in low/lower-middle-income countries, upper-
middle-income countries, and high-income countries
(Additional file 1: Table S1). Adults were selected using
probability sampling methods designed to generate popula-
tion representative samples, and interviews were conducted
face to face in respondent homes. A total of 123,628 re-
spondents from 25 countries participated in the present
study. Informed consent was obtained according to proto-
cols endorsed by local Institutional Review Boards.
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Within-country sampling methods are described in detail
elsewhere [37, 38].
Measures
Mental disorders
Lifetime and 12-month mental disorders were assessed
with the WHO Composite International Diagnostic
Interview (CIDI) [39]. To reduce respondent burden, in-
terviews were administered in two parts. All respondents
completed part I, assessing core mental disorders. Part
II, assessing other disorders and correlates, was adminis-
tered to all respondents with any lifetime part I diagno-
sis and a probability subsample of other part I
respondents. Part II data were weighted so that weighted
prevalence estimates are identical to those in the part I
sample.
We included the following internalizing disorders:
anxiety disorders (panic disorder, agoraphobia, GAD, so-
cial anxiety disorder, SP, post-traumatic stress disorder
[PTSD], separation anxiety disorder), mood disorders
(MDD and/or dysthymia, bipolar disorder [I, II, or sub-
threshold]), and eating disorders (bulimia nervosa, binge
eating disorder). CIDI diagnoses have shown generally
good concordance with diagnoses based on blinded
Structured Clinical Interview for DSM-IV (SCID) re-
appraisal [40]. Age of onset was assessed with retro-
spective reports. Persistence was defined as the presence
of the disorder in the 12months before interview among
lifetime cases.
Specific phobia
The CIDI distinguishes between six SP subtypes: animals,
still water or weather, high places, blood-injection-injury,
closed spaces, and flying. For each participant, we deter-
mined how many subtypes with an age of onset prior to
age 13 were reported. Because few participants reported
more than four subtypes, we collapsed participants report-
ing four or more subtypes into a single group. Participants
who developed SP later in life were included in the group
of participants without childhood SP.
Impairment and suicidality
Severe role impairment due to SP was assessed with a
modified Sheehan Disability Scale (SDS) [41]. Respon-
dents with 12-month SP rated its interference with func-
tioning in four domains (home management, work, close
relationships, and social life) on a scale of 0–10 during
the worst month in the past year. Severe impairment
was defined as a score ≥ 7 in at least one domain. Re-
spondents with lifetime SP were asked whether they had
ever sought treatment specifically for SP.
All respondents were asked how many days in the past
30 days they were totally unable to work or carry out
normal activities because of any physical or mental
health problems, whether they had ever seriously
thought about committing suicide, and, if so, whether
they had ever made a plan or attempted suicide. We also
examined serious mental illness (SMI), which was de-
fined as meeting criteria for 12-month bipolar I disorder
or having another 12-month mood or anxiety disorder
(other than SP) with either severe role impairment or a
past-year suicide attempt [42].
Statistical analysis
We tested the linear association of the number of
early-onset SP subtypes, both within the whole sample
and within the subsample with childhood SP, using logis-
tic regression for dichotomous variables and linear re-
gression for continuous variables (SAS 9.4). We used the
actuarial method to determine the age of onset of co-
morbid disorders and tested for differences in age of on-
set depending on the number of SP subtypes using
discrete-time logistic regression in the subsample with
the comorbid disorder. We also used the actuarial
method to calculate the projected lifetime risk of any in-
ternalizing disorder, which takes into account that re-
spondents who have not had a disorder yet may still
develop the disorder later in life. We also estimated
population attributable fractions (PAFs) [43], which indi-
cate the fraction of an outcome in the population that is
attributable to childhood SP (assuming a causal relation-
ship, noting that the latter can only be confirmed experi-
mentally). All analyses controlled for country of origin
of the participant. Because the data were clustered and
weighted, standard errors were estimated using the
Taylor series linearization method (SUDAAN 11.0.1).
Significance tests were evaluated using α = 0.005 (two-
sided) to reduce the chance of false-positive findings
given the many tests performed.
As sensitivity analyses, we tested interactions between
the number of SP subtypes and age group (18–34, 35–
49, and 50+ years old), to examine whether associations
between childhood phobia and mental health outcomes
persisted into older adulthood. We also tested whether
associations were found for participants with and with-
out current internalizing psychopathology and for partic-
ipants from high-income countries as well as those from
low- or middle-income countries.
Results
Specific phobia
Out of 123,628 participants, 51.8% were female and the
mean age was 42.0 (SD = 16.9). Lifetime and 12-month
SP prevalence was 7.6% and 5.7%, respectively. Most re-
spondents reported onset before the age of 13, resulting
in a 5.9% lifetime prevalence of childhood-onset SP.
Prevalence was 3.3% for one early-onset subtype, 1.5% for
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two, 0.6% for three, and 0.5% for 4+ (Table 1). Persistence
was high and increased with number of subtypes (from
73.4% for participants with one subtype to 85.2% for those
with 4+ subtypes, OR = 1.2, p < 0.001). Severe impairment
due to SP and treatment for SP were uncommon (17.5–
26.5%), but increased with an increasing number of sub-
types (OR = 1.1–1.3, p = 0.004 and < 0.001).
Internalizing disorder comorbidity
Lifetime prevalence of any internalizing disorder in-
creased from 18.2% among those without childhood SP
to 46.3% among those with one SP subtype and 75.6%
among those with 4+ subtypes (OR = 2.4 in the total
sample and 1.6 in the SP subsample, p < 0.001) (Table 2).
Figure 1 shows the projected risk of any internalizing
disorder by age and number of SP subtypes. Examining
separate disorder groupings, similar patterns were appar-
ent for anxiety disorders (OR = 2.4 (total sample) and 1.6
(SP subsample), p < 0.001), mood disorders (OR = 1.9
(total sample) and 1.4 (SP subsample), p < 0.001), and
eating disorders (OR = 1.8 (total sample) and 1.3 (SP
subsample), p < 0.001 and p = 0.003). Only 0.6% of re-
spondents without SP and 4.2% of those with one SP
subtype met criteria for 4+ internalizing disorders (other
than SP), compared to 19.4% of respondents with 4+ SP
subtypes (OR = 2.6 (total sample) and 1.7 (SP sub-
sample), p < 0.001). SP preceded other internalizing dis-
orders in 79.4% of comorbid cases; in an additional
10.8% of cases, the onset of SP and another internalizing
disorder coincided.
Estimated PAFs for any childhood SP ranged from
8.7% for MDD to 38.8% for agoraphobia (Additional file 1:
Table S2). This means that if the associations found here
are accurate reflections of causal effects either of child-
hood SP or of a latent liability that could be successfully
treated by early intervention with childhood SP, the
population-level lifetime prevalence of these disorders
would be expected to decrease proportionally by 8.7–
38.8%. The PAFs for any internalizing disorder and
for 4+ internalizing disorders were 10.2% and 39.4%,
respectively.
Persistence of any lifetime internalizing disorder in-
creased from 47.9% for respondents without childhood
SP to 59.0% for those with one SP subtype and 79.1% for
those with 4+ subtypes (OR = 1.4 (total sample) and 1.3
(SP subsample), p < 0.001) (Table 3). Examining separate
disorder groupings, similar patterns were found for anx-
iety disorders (OR = 1.4 (total sample) and 1.2 (SP sub-
sample), p < 0.001) and mood disorders (OR = 1.3 (total
sample) and 1.2 (SP subsample), p < 0.001), but not for
eating disorders (OR = 1.1 (total sample) and 0.8 (SP
subsample), p = 0.164–0.295).
Median age of onset of comorbid internalizing disor-
ders generally decreased with increasing number of
early-onset SP subtypes (Table 4), especially for agora-
phobia, GAD, panic disorder, and MDD/dysthymia. For
GAD, median age of onset was 39 for those without
childhood SP, 37 for those with one subtype, and 28 for
those with 4+ subtypes (OR = 1.2 (total sample and SP
subsample), p < 0.001). Similarly, median age of onset
decreased from 21 to 12 for agoraphobia, from 33 to 18
for panic disorder, and from 38 to 29 for MDD/dys-
thymia (OR = 1.2 (total sample) and 1.1–1.3 (SP sub-
sample), p < 0.001). For social anxiety disorder, there was
also a consistent, though slight, decrease in age of onset
with an increasing number of SP subtypes (from 14 to
12, OR = 1.2 (total sample) and 1.3 (SP subsample), p <
0.001). For PTSD, separation anxiety disorder, and bipo-
lar disorder, patterns were less consistent (OR = 1.0–1.2,
p < 0.001–0.235).
Impairment, suicidality, and serious mental illness
Respondents without childhood SP reported a mean
(SE) of 1.05 (0.03) days out of role in the past 30 days,
compared to 1.80 (0.19) days among respondents with
one SP subtype and 3.53 (0.53) days among those with 4
+ subtypes (B = 0.56 (total sample) and 0.49 (SP sub-
sample), p < 0.001) (Table 5). Suicidality was also rela-
tively common among those with childhood SP, with
Table 1 Prevalence and characteristics of specific phobia
Any
specific
phobia
Any
early-
onset
specific
phobia
Number of subtypes Test of linear effect
1 2 3 4+
% (SE) % (SE) % (SE) % (SE) % (SE) % (SE) OR (95% CI) p value
Lifetime prevalence 7.6 (0.1) 5.9 (0.1) 3.3 (0.1) 1.5 (0.0) 0.6 (0.0) 0.5 (0.0) – –
12-month prevalence 5.7 (0.1) 4.4 (0.1) 2.4 (0.1) 1.1 (0.0) 0.5 (0.0) 0.4 (0.0) – –
Persistence 74.3 (0.6) 75.2 (0.7) 73.4 (0.9) 75.2 (1.3) 77.6 (1.8) 85.2 (1.8) 1.2* (1.1–1.3) < 0.001
Severe disability 19.1 (0.6) 19.7 (0.6) 17.5 (0.8) 20.2 (1.4) 24.0 (2.0) 26.5 (2.4) 1.3* (1.1–1.4) < 0.001
Treatment for specific phobia 22.4 (0.5) 20.8 (0.6) 19.1 (0.8) 22.9 (1.2) 22.4 (1.7) 22.8 (2.0) 1.1* (1.0–1.2) 0.004
*p < 0.005
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Table 2 Prevalence of comorbid internalizing disorders, as a function of the number of specific phobia subtypes
Comorbid disorder Number of subtypes Test of linear effect (total
sample)
Test of linear effect (SP
cases only)
0 1 2 3 4+
% (SE) % (SE) % (SE) % (SE) % (SE) OR (95% CI) p value OR (95% CI) p value
Agoraphobia 0.8 (0.0) 5.1 (0.4) 9.5 (0.8) 17.4 (2.0) 21.2 (2.3) 2.6* (2.4–2.7) < 0.001 1.7* (1.5–1.9) < 0.001
Generalized anxiety disorder 3.5 (0.1) 9.7 (0.6) 14.2 (1.1) 21.0 (1.8) 21.3 (2.6) 1.8* (1.7–1.9) < 0.001 1.4* (1.3–1.5) < 0.001
Panic disorder 1.4 (0.0) 5.5 (0.5) 8.8 (0.7) 12.6 (1.5) 15.8 (1.8) 2.0* (1.9–2.1) < 0.001 1.5* (1.3–1.6) < 0.001
Post-traumatic stress disorder 2.9 (0.1) 9.0 (0.6) 15.3 (1.2) 18.5 (1.8) 22.2 (2.3) 1.9* (1.8–2.0) < 0.001 1.4* (1.3–1.6) < 0.001
Separation anxiety disorder 3.9 (0.1) 12.7 (0.9) 19.7 (1.7) 27.2 (2.5) 27.4 (2.7) 1.9* (1.8–2.0) < 0.001 1.4* (1.2–1.5) < 0.001
Social anxiety disorder 3.3 (0.1) 14.9 (0.8) 23.2 (1.3) 31.3 (2.3) 38.2 (2.8) 2.3* (2.2–2.4) < 0.001 1.5* (1.4–1.6) < 0.001
Any anxiety disorder 10.5 (0.2) 33.6 (1.1) 47.0 (1.7) 62.4 (2.3) 66.1 (2.8) 2.4* (2.3–2.5) < 0.001 1.6* (1.5–1.7) < 0.001
Major depression/dysthymia 10.5 (0.2) 24.1 (0.9) 30.1 (1.4) 36.2 (2.5) 34.1 (2.7) 1.6* (1.6–1.7) < 0.001 1.2* (1.2–1.3) < 0.001
Bipolar disorder 1.8 (0.1) 5.7 (0.5) 10.0 (0.9) 12.7 (1.5) 17.3 (1.9) 1.9* (1.8–2.0) < 0.001 1.5* (1.3–1.6) < 0.001
Any mood disorder 12.0 (0.2) 28.8 (1.0) 39.3 (1.5) 47.8 (2.5) 50.9 (3.0) 1.9* (1.8–1.9) < 0.001 1.4* (1.3–1.5) < 0.001
Bulimia nervosa 0.6 (0.0) 2.0 (0.3) 3.6 (0.7) 6.8 (1.6) 5.9 (1.6) 2.0* (1.8–2.2) < 0.001 1.7* (1.4–2.0) < 0.001
Binge eating disorder 1.4 (0.1) 5.7 (0.8) 5.3 (0.8) 6.6 (1.7) 6.3 (1.7) 1.7* (1.5–1.8) < 0.001 1.0 (0.8–1.3) 0.746
Any eating disorder 1.9 (0.1) 7.2 (0.9) 8.3 (1.0) 12.4 (2.0) 11.4 (2.2) 1.8* (1.7–1.9) < 0.001 1.3* (1.1–1.5) 0.003
Any internalizing disorder 18.2 (0.2) 46.3 (1.2) 61.1 (1.7) 75.6 (2.1) 75.6 (2.7) 2.4* (2.3–2.5) < 0.001 1.6* (1.5–1.8) < 0.001
Exactly 1 internalizing disorder 12.3 (0.2) 24.0 (1.0) 27.6 (1.5) 26.8 (2.2) 21.6 (2.4) 1.4* (1.3–1.4) < 0.001 1.0 (0.9–1.1) 0.677
Exactly 2 internalizing disorders 4.0 (0.1) 12.2 (0.7) 15.2 (1.2) 21.6 (2.0) 19.7 (2.2) 1.7* (1.6–1.8) < 0.001 1.2* (1.1–1.3) < 0.001
Exactly 3 internalizing disorders 1.4 (0.0) 5.9 (0.5) 9.2 (0.8) 12.8 (1.5) 14.9 (1.8) 2.0* (1.9–2.1) < 0.001 1.4* (1.2–1.5) < 0.001
4+ internalizing disorders 0.6 (0.0) 4.2 (0.4) 9.0 (0.8) 14.4 (1.7) 19.4 (2.6) 2.6* (2.4–2.8) < 0.001 1.7* (1.6–2.0) < 0.001
Italics indicate the main groups of disorders. *p < 0.005
Fig. 1 Projected risk of any internalizing disorder by age 75, by number of childhood specific phobia subtypes. Projected risk was calculated
using the actuarial method and accounts for censoring of participants who have not yet reached the age of 75 by the time of the interview
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31.8% of those with 4+ subtypes reporting lifetime sui-
cidal ideation, compared to only 7.5% of those without
childhood phobia and 18.8% of those with one SP sub-
type (OR = 1.6 (total sample) and 1.3 (SP subsample), p
< 0.001). Furthermore, 36.8% of respondents with 4+
subtypes reported a 12-month SMI, compared to just
3.5% of those without childhood phobia and 12.7% of
those with one subtype (OR = 2.1 (total sample) and 1.5
(SP subsample), p < 0.001). PAFs for suicidality and SMI
ranged from 13.9% for suicidal ideation to 20.4% for sui-
cide attempts (Additional file 1: Table S3).
Sensitivity analyses
Associations of SP subtype number with prevalence,
persistence, and severity of secondary comorbid
disorders were generally consistent across age groups
(Additional file 1: Table S4 and 5), suggesting that the
associations described above are generally stable over
the life course. Likewise, we found associations of SP
subtype number with the lifetime prevalence of comor-
bid disorders and suicidality in participants with and
without a current 12-month internalizing disorder (Add-
itional file 1: Table S6-S10). Finally, the prevalence of
specific phobia, comorbid disorders, and suicidality were
all lower in low- or middle-income countries compared
to high-income countries; however, the associations be-
tween number of SP subtypes and comorbidity or suicid-
ality were similar regardless of country income level
(Additional file 1: Table S11-16).
Discussion
Principal findings
In this study, we used a large cross-national sample to
explore the associations of childhood generalized SP
Table 3 Persistence of comorbid internalizing disorders, as a function of the number of specific phobia subtypes
Comorbid disorder Number of subtypes Test of linear effect (total
sample)
Test of linear effect (SP
cases only)
0 1 2 3 4+
% (SE) % (SE) % (SE) % (SE) % (SE) OR (95% CI) p value OR (95% CI) p value
Agoraphobia 57.8 (2.6) 67.6 (3.9) 64.6 (5.1) 63.6 (6.6) 86.4 (3.2) 1.3* (1.1–1.4) < 0.001 1.3* (1.1–1.6) 0.002
Generalized anxiety disorder 46.2 (1.1) 52.3 (3.0) 56.3 (3.7) 51.0 (4.7) 68.7 (5.3) 1.2* (1.1–1.3) < 0.001 1.1 (1.0–1.3) 0.155
Panic disorder 56.1 (1.9) 59.3 (4.1) 65.7 (3.9) 63.6 (5.8) 80.7 (4.7) 1.2* (1.1–1.4) < 0.001 1.3* (1.1–1.6) 0.003
Post-traumatic stress disorder 46.0 (1.5) 53.4 (3.5) 56.0 (4.0) 59.6 (4.9) 50.9 (5.4) 1.2* (1.0–1.3) 0.003 1.0 (0.9–1.2) 0.821
Separation anxiety disorder 20.4 (1.3) 20.3 (3.1) 24.2 (3.1) 23.3 (4.2) 26.3 (4.3) 1.1 (1.0–1.2) 0.109 1.1 (0.9–1.3) 0.345
Social anxiety disorder 56.2 (1.3) 65.3 (2.7) 73.9 (2.8) 73.4 (3.6) 80.2 (3.5) 1.3* (1.2–1.5) < 0.001 1.2 (1.0–1.3) 0.027
Any anxiety disorder 48.9 (0.8) 59.5 (1.8) 65.4 (2.1) 65.5 (2.9) 76.0 (2.9) 1.4* (1.3–1.4) < 0.001 1.2* (1.1–1.3) < 0.001
Major depression/dysthymia 39.7 (0.6) 48.8 (2.0) 51.5 (2.7) 56.3 (3.8) 63.3 (4.5) 1.3* (1.2–1.4) < 0.001 1.2 (1.0–1.3) 0.007
Bipolar disorder 56.7 (1.6) 57.4 (4.3) 67.9 (4.8) 70.2 (5.4) 77.5 (4.9) 1.2* (1.1–1.4) < 0.001 1.4* (1.2–1.8) 0.001
Any mood disorder 41.9 (0.5) 50.2 (1.8) 55.3 (2.4) 59.7 (3.1) 68.0 (3.3) 1.3* (1.2–1.4) < 0.001 1.2* (1.1–1.4) < 0.001
Any eating disorder 42.9 (2.3) 54.0 (5.7) 55.7 (5.7) 38.1 (8.8) 45.1 (8.9) 1.1 (0.9–1.2) 0.295 0.8 (0.6–1.1) 0.164
Any internalizing disorder 47.9 (0.5) 59.0 (1.5) 66.1 (2.0) 70.5 (2.5) 79.1 (2.5) 1.4* (1.4–1.5) < 0.001 1.3* (1.2–1.4) < 0.001
Persistence is defined as the presence of a 12-month disorder among lifetime cases with that disorder. Because of low prevalence, persistence of individual eating
disorders was not assessed
Italics indicate the main groups of disorders. *p < 0.005
Table 4 Age of onset of comorbid disorders, as a function of the number of specific phobia subtypes
Comorbid disorder Number of subtypes Test of linear effect
(whole sample)
Test of linear effect
(SP cases only)0 1 2 3 4+
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) OR (95% CI) p value OR (95% CI) p value
Agoraphobia 21 (13–35) 21 (13–39) 20 (13–40) 16 (8–31) 12 (8–17) 1.2* (1.1–1.2) < 0.001 1.3* (1.2–1.4) < 0.001
Generalized anxiety disorder 39 (26–54) 37 (24–52) 35 (21–52) 33 (20–44) 28 (18–46) 1.2* (1.1–1.2) < 0.001 1.2* (1.1–1.2) < 0.001
Panic disorder 33 (21–49) 29 (19–41) 35 (18–60) 24 (14–41) 18 (11–27) 1.2* (1.2–1.3) < 0.001 1.2* (1.1–1.3) < 0.001
Post-traumatic stress disorder 36 (21–54) 33 (20–49) 36 (19–53) 35 (19–75) 33 (19–64) 1.1* (1.0–1.1) 0.002 1.1 (1.0–1.2) 0.166
Separation anxiety disorder 19 (10–31) 19 (8–29) 18 (8–30) 14 (8–36) 17 (8–28) 1.0 (1.0–1.1) 0.074 1.0 (1.0–1.1) 0.235
Social anxiety disorder 14 (9–18) 13 (10–16) 13 (8–16) 13 (8–17) 12 (7–15) 1.2* (1.1–1.2) < 0.001 1.3* (1.3–1.4) < 0.001
Major depression/dysthymia 38 (25–53) 33 (22–48) 34 (21–51) 30 (18–50) 29 (15–46) 1.2* (1.1–1.2) < 0.001 1.1* (1.0–1.2) 0.001
Bipolar disorder 25 (18–38) 26 (18–44) 28 (19–45) 33 (20–45) 24 (18–32) 1.0 (1.0–1.1) 0.169 1.2* (1.1–1.3) 0.001
Median age of onset was determined using the actuarial method. Differences in age of onset were tested with a discrete-time logistic regression, with the sample
limited to participants who developed the comorbid disorder, and with number of early phobia subtypes time-varying until age 13
*p < 0.005
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with the prevalence, persistence, and severity of other in-
ternalizing disorders. Among the 7.6% of participants
reporting lifetime SP, most (78%) had already developed
the disorder before age 13. Childhood SP was highly per-
sistent, although severe disability and treatment-seeking
for SP were uncommon. Many respondents with child-
hood SP reported multiple phobias (44%), with 8% even
reporting four or more phobias. Childhood SP was
strongly associated with prevalence, persistence, and se-
verity of other internalizing disorders as well as with an
early age of onset of these disorders. It was also associ-
ated with increased number of days out of role and SMI,
as well as with suicidality. At a population level, 8.7–
38.8% of all internalizing disorders and 13.9–20.4% of all
suicidality or SMI were associated with childhood SP.
Furthermore, associations persisted throughout the life-
span. Of particular importance, participants with gener-
alized specific phobia had much worse outcomes than
those with a single fear. For example, 17% of those with
four or more phobias reported a suicide attempt, com-
pared to only 7% of those with a single phobia.
SP is generally viewed as a relatively mild disorder that
causes less disability than other mood or anxiety disor-
ders [24]. However, our results suggest that childhood
SP, particularly when generalized, is strongly associated
with poor long-term outcomes in the internalizing do-
main. Caution is needed since these results are based on
a retrospective cohort design and recall error could lead
to bias. However, the stability of the results across the
age range of this very large and diverse sample suggests
that the pattern is worthy of future investigation.
The present study is a practical application of sugges-
tions made in the Hierarchical Taxonomy Of Psycho-
pathology (HiTOP) initiative, which aims to develop an
empirically driven nosology of psychopathology [44].
One fundamental aspect of HiTOP is its reliance on
quantitative, rather than dichotomous measures, to more
closely approximate the true nature of psychopathology.
Although we have examined a specific disorder, we have
used a more quantitative approach than the strictly
DSM approach by looking at the number of SP subtypes.
Furthermore, we chose to focus on specific phobia be-
cause it tends to be the earliest manifestation of an in-
ternalizing liability, not because we think it is unique.
The results suggest that it might be possible to identify
at least some of the people with a strong internalizing li-
ability in childhood even though their childhood disor-
ders typically are not severe.
A similar approach could be applied to other psycho-
pathology domains. For instance, the externalizing do-
main includes substance use disorders, which usually
first appear in late adolescence, as well as disorders with
childhood onset, such as attention deficit hyperactivity
disorder (ADHD) [3]. For other domains, such as
thought disorders, subclinical psychotic experiences or
personality traits like suspiciousness might be relevant
[45, 46]. Examination of personality traits might also
help refine the early identification of persons with high
internalizing or externalizing liabilities.
From the point of view of prevention, one might argue
whether targeted interventions should be aimed at
everyone with childhood SP or at a smaller or larger
group. If resources are limited, targeting those with mul-
tiple phobias is reasonable, as the tendency to generalize
fear appears to predict a particularly poor prognosis. For
instance, reducing the risk for just this very small group
(0.5%) to that of people without childhood SP could pre-
vent 1.1–7.8% of other internalizing disorders and 3.5%
of all suicide attempts. However, even participants with
a single phobia had increased risks of unfavorable
Table 5 Days out of role, suicidality, and serious mental illness
Category Subcategory Number of subtypes Test of linear effect
(total sample)
Test of linear effect
(SP cases only)0 1 2 3 4+
Mean
(SE)
Mean
(SE)
Mean
(SE)
Mean
(SE)
Mean
(SE)
B (SE) p
value
B (SE) p
value
Days out of role in the past 30
days
1.05
(0.03)
1.80
(0.19)
1.94
(0.17)
2.51
(0.30)
3.53
(0.53)
0.56* (0.06) <
0.001
0.49* (0.15) <
0.001
% (SE) % (SE) % (SE) % (SE) % (SE) OR (95% CI) p
value
OR (95% CI) p
value
Suicidality Ideation 7.5 (0.1) 18.8 (0.8) 23.7 (1.3) 30.7 (2.0) 31.8 (2.4) 1.6* (1.6–
1.7)
<
0.001
1.3* (1.2–
1.3)
<
0.001
Plan 2.3 (0.1) 6.7 (0.5) 9.5 (0.8) 13.6 (1.4) 14.1 (1.8) 1.7* (1.6–
1.8)
<
0.001
1.3* (1.2–
1.4)
<
0.001
Attempt 2.0 (0.0) 6.5 (0.4) 8.4 (0.7) 13.4 (1.3) 16.8 (1.7) 1.7* (1.7–
1.8)
<
0.001
1.4* (1.3–
1.5)
<
0.001
Serious mental illness 3.5 (0.1) 12.7 (0.7) 20.9 (1.2) 27.8 (2.1) 36.8 (2.7) 2.1* (2.0–
2.2)
<
0.001
1.5* (1.4–
1.7)
<
0.001
*p < 0.005
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outcomes. The population attributable fraction for sui-
cide attempts for all childhood SP, for instance, was
20.4%, showing that much greater benefits could be ob-
tained by targeting this larger group. Furthermore, previ-
ous research has found that most children reporting a
specific fear do not meet SP criteria [31]. It is currently
unclear whether such fearfulness is harmless or a sign of
an internalizing vulnerability, for instance when fearful-
ness is generalized.
As our study is observational, we cannot establish
causality. We hypothesize that the associations are not
directly causal, but that both childhood SP and later out-
comes are expressions of a latent internalizing vulner-
ability. Although SP is a promising target in part
because it is a relatively easy to treat disorder [47] that
nevertheless often remains untreated, it is unclear
whether treatment specifically for SP would have sub-
stantial effects on internalizing outcomes later in life.
Exposure is a common element in cognitive behavioral
therapy, so broader effects on the underlying vulnerabil-
ity are plausible, and there is some evidence to suggest
that treatment for phobia can lead to improvement in
already-existing comorbid anxiety disorders [48]. Since
even single-session behavioral therapy can be sufficient
for SP [49], and since up to 20% of suicide attempts and
19% of SMI are attributable to childhood SP (assuming a
causal relationship), it would be highly worthwhile to
examine whether early treatment of specific phobia has
a substantial effect on these other outcomes.
In contrast to most previous research regarding SP,
which used participant samples from high-income West-
ern countries, our sample included a diverse set of coun-
tries. We found that both SP and our main outcomes,
comorbidity and suicidality, were less prevalent in low-
and middle-income countries than in high-income coun-
tries. However, the associations between childhood (gen-
eralized) SP and these outcomes were remarkably
similar across country income levels. This suggests that
childhood generalized SP might be a globally useful and
not culturally specific marker for at-risk children. How-
ever, treatment rates for childhood-onset SP are even
lower in low- or middle-income countries (12.7%) than
in high-income countries (26.8%), and it may be difficult
to detect and provide early intervention to these chil-
dren if resources are scarce. Ideally, to reach as many
people as possible, any screening or intervention pro-
gram for childhood generalized SP should also be feas-
ible in countries with relatively few specialist mental
health care providers.
Strengths and limitations
The World Mental Health Surveys provide a unique op-
portunity to examine childhood SP and its relationship to
other internalizing disorders in a very large sample from a
diverse set of countries using a common protocol and
instrument. However, there are also several important limi-
tations. First, data are derived from a cross-sectional inter-
view of adult participants, and age of onset is therefore
estimated retrospectively. While the survey was designed
using modern cognitive interviewing methods as a way to
encourage active memory search and improve recall accur-
acy [50], some recall bias doubtlessly persists. Mild SP may
have been forgotten, so our sample may not be fully repre-
sentative of all children with SP. However, while some of
our research questions could also be examined with exist-
ing longitudinal studies, no longitudinal studies with a suf-
ficiently large sample size exists that could examine all the
questions considered here. We also took several steps to in-
vestigate whether recall bias could explain our results.
Firstly, we performed sensitivity analyses in the separate
age groups and found broadly similar results in the youn-
gest age group (18–34 years old), for whom recall bias
should be least problematic, compared to the oldest age
group (50+ years old). Presence of current psychopathology
could also lead to recall bias. If respondents with current
psychopathology are more likely to recall symptoms they
suffered previously, including specific phobias, this could
lead to a spurious association between childhood SP and
comorbidity. However, we also found strong associations
between number of childhood SP subtypes and lifetime co-
morbidity within the subgroup of respondents that did not
report a 12-month internalizing disorder. Secondly, the ob-
servational design precludes causal inferences. Finally, the
CIDI does not assess all phobias. Consequently, we may
have underestimated the number of childhood SP subtypes.
Conclusions
In conclusion, this study has shown that childhood
generalized SP, as assessed in a retrospective survey, is
strongly associated with poor outcomes in the internaliz-
ing domain of psychopathology throughout the life
course. While our study cannot establish whether child-
hood SP is causally associated with these later outcomes
or whether some other factor, such as an underlying
internalizing vulnerability, explains the association, it
clearly identifies children with generalized SP as a
high-risk group. Respondents with childhood SP not
only were more likely than other respondents to develop
internalizing disorders, but developed them at an earlier
age and had a more persistent and severe course, includ-
ing more disability, suicidality, and serious mental ill-
ness. Although even respondents with a single childhood
SP subtype had an elevated risk of poor outcomes, risk
was much higher among respondents who reported mul-
tiple childhood SP subtypes. Children with generalized
SP might therefore be an important target group for
early intervention to reduce internalizing psychopath-
ology across the lifespan.
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